Vantage logo

The big cap empire strikes back

If the first three quarters of 2019 were dominated by pricing fears, the last saw a remarkable comeback for biopharma.

Vantage logo

Big caps provide a safe haven

As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.